USPTO Examiner CHANDRAKUMAR NIZAL S - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19040329TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHJanuary 2025May 2025Allow301YesNo
18820232USE OF REBOXETINE TO TREAT NARCOLEPSYAugust 2024March 2025Allow610YesNo
18809731DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICEAugust 2024April 2025Allow811YesNo
18787536Systems and methods for the production of levulinic acid, furfural, and formic acidJuly 2024October 2024Allow200YesNo
18765167SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJuly 2024December 2024Allow510NoNo
18670653LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINEMay 2024July 2024Allow200NoNo
18654002BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024October 2024Allow501NoNo
18573904NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOFDecember 2023June 2024Allow600YesNo
185295156-(4-HYDROXYPHENYL)-2-(2-ETHOXYETHOXY)-4-(4-METHOXYPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUNDDecember 2023July 2024Allow721YesNo
18521663SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITHNovember 2023April 2025Allow1701NoNo
185081641,4-DIVINYLPHENYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(PiPR3)2 MOIETIES WITH 8-MERCAPTOQUINOLATO CO-LIGAND AS AN ORGANIC CATALYSTNovember 2023December 2024Allow1321NoNo
183855788-((3,4-DIHYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023February 2025Allow1530NoYes
183855618-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023June 2025Abandon1940NoNo
183847718-((3-FORMYL-4-HYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023February 2025Allow1630YesYes
183847858-[(2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL]NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023May 2025Abandon1830NoNo
18384197FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPYOctober 2023March 2025Allow1711YesNo
18492746PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEINOctober 2023January 2025Allow1500YesNo
18379559N-(NAPHTHALEN-1-YLCARBAMOTHIOYL)FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023December 2023Allow200YesNo
18475724TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHSeptember 2023February 2025Allow1611NoNo
18233090CONTRACEPTIVE COMPOUNDS AND METHODSAugust 2023December 2024Allow1600YesNo
18365877SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEAugust 2023February 2024Allow610YesNo
18229353PLK1 SELECTIVE DEGRADATION INDUCING COMPOUNDAugust 2023July 2025Abandon2301NoNo
18220856CANNABIS BASED THERAPEUTIC AND METHOD OF USEJuly 2023July 2025Allow2410NoNo
18347808ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTSJuly 2023November 2024Allow1600YesNo
18339227MACROCYCLIC COMPOUND AND USES THEREOFJune 2023May 2025Allow2311NoNo
18209699BROMOCRIPTINE FORMULATIONSJune 2023December 2024Allow1800YesNo
18206953PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINESJune 2023December 2023Allow610YesNo
18204566ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOFJune 2023June 2025Allow2410YesNo
18318939AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGSMay 2023December 2023Allow6001YesNo
18318158METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOODMay 2023June 2025Abandon2501NoNo
18141999DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOFMay 2023June 2025Allow2510YesNo
18307174SUBSTITUTED ALKYLPHENOLS AS HCN1 ANTAGONISTSApril 2023November 2024Allow1900YesNo
18305611FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTORApril 2023June 2025Abandon2610NoNo
18137766CANNABINOID CONJUGATE MOLECULESApril 2023November 2023Allow701YesNo
18304764ORGANIC ELECTRO-OPTIC CHROMOPHORESApril 2023March 2025Allow2301YesNo
18303267USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERApril 2023June 2025Abandon2610YesNo
18135225COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURYApril 2023June 2025Abandon2610YesNo
18297973ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERSApril 2023July 2023Allow300NoNo
18131052CANNABIS BASED THERAPEUTIC AND METHOD OF USEApril 2023March 2025Allow2410YesNo
18130178CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASESApril 2023September 2024Allow1701YesNo
18185555SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOFMarch 2023May 2025Abandon2601NoNo
18121694HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORSMarch 2023October 2024Allow1910YesNo
18119564PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMALMarch 2023March 2025Allow2520YesNo
18119751COUMARIN COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023December 2023Allow920YesNo
18117257Compositions and Methods of Modulating Short-Chain Dehydrogenase ActivityMarch 2023June 2025Abandon2711YesNo
18115966TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHMarch 2023May 2024Allow1400YesNo
18114055BORATE SALTS, POLYMERS AND COMPOSITESFebruary 2023July 2024Allow1601NoNo
18169716BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSESFebruary 2023September 2024Allow1910NoNo
18157593CO-CRYSTALS OF BOSCALID AND TRIAZOLESJanuary 2023July 2024Allow1801YesNo
18096272COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITYJanuary 2023April 2025Abandon2711NoNo
18152098DENDRILLA MEMBRANOSA COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOFJanuary 2023February 2025Allow2521NoNo
18069943METHOD FOR MANUFACTURING METHYLTETRAHYDROPHTHALIC ANHYDRIDEDecember 2022August 2024Allow6030YesNo
18084307AMINO ACID COMPOUNDS AND METHODS OF USEDecember 2022May 2024Allow1700YesNo
18067456READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDESDecember 2022January 2024Allow1321YesNo
18082973Methods of Treating Residual Lesions of Vascular AnomaliesDecember 2022May 2025Abandon2920YesNo
18062683Fospropofol Salts, Methods And CompositionsDecember 2022March 2025Allow2720YesNo
18075664CHEMICAL COMPOUNDSDecember 2022December 2024Abandon2401NoNo
17990427CD16A BINDING AGENTS AND USES THEREOFNovember 2022July 2024Allow1901YesNo
17925923ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOFNovember 2022June 2025Allow3100YesNo
17982859CANNABINOID CONJUGATE MOLECULESNovember 2022March 2023Allow401YesNo
17982779CANNABINOID CONJUGATE MOLECULESNovember 2022March 2023Allow501YesNo
17982233THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDSNovember 2022February 2025Allow2711YesNo
17974804COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITYOctober 2022May 2025Abandon3021NoNo
18048016COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESISOctober 2022December 2024Allow2610YesNo
17967767SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEOctober 2022May 2024Allow1910NoNo
17964491TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORSOctober 2022October 2024Allow2421YesNo
17954740Methods for Producing Nitroso Compound and Quinoxaline CompoundSeptember 2022May 2024Allow1900YesNo
17955182THERAPEUTIC CONJUGATESSeptember 2022April 2024Allow1901YesNo
17934964POST POLYMERIZATION MODIFICATION IN FLOWSeptember 2022October 2024Allow2520YesNo
17948162AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUP AND USE OF THE SAMESeptember 2022October 2024Allow2501YesNo
17948157PHARMACEUTICAL COMPOSITION COMPRISING AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUPSeptember 2022April 2024Allow1901YesNo
17948165METHOD FOR PREPARING AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUPSeptember 2022June 2024Allow2120YesNo
17946898Small Molecule Binders of the Oncogenic Fusion Transcription Factor PAX3-FOXO1September 2022December 2023Allow2301YesNo
17893292SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATESAugust 2022November 2023Allow1510YesNo
17819695PROCESS FOR PRODUCING SUBSTITUTED AMINO ALCOHOLSAugust 2022April 2025Abandon3220YesNo
17887854MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITORAugust 2022September 2024Allow2511YesNo
17886807TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORSAugust 2022March 2024Allow1910NoNo
17818378COMPOSITION FOR PREVENTING OR TREATING KELOIDAugust 2022May 2024Allow2121NoNo
17880720MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATORAugust 2022February 2025Allow3020YesYes
17880101METHOD OF TREATING STIMULANT USE DISORDER USING A COMBINATION OF TOPIRAMATE AND PHENTERMINEAugust 2022October 2024Allow2620YesNo
17871065FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOFJuly 2022March 2024Allow2010NoNo
17867216DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTSJuly 2022January 2025Abandon3021YesNo
178643073-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOFJuly 2022November 2023Allow1600YesNo
17856502PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVISJuly 2022March 2024Allow2000YesNo
17856605SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJuly 2022September 2022Allow200YesNo
17852525COSMETIC COMPOSITION CONTAINING A RHEOLOGICAL-MODIFYING AND STABILIZING POLYMER BLENDJune 2022October 2024Allow2721YesYes
17853623SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJune 2022August 2022Allow200YesNo
17852774METHOD FOR TREATMENT OF PANCREATITISJune 2022June 2025Allow3610YesNo
17852475COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPYJune 2022February 2025Allow3221YesNo
17845767USE OF REBOXETINE TO TREAT NARCOLEPSYJune 2022February 2024Allow2000YesNo
17843569CRYSTALLINE FORMS OF A BIPHENYL COMPOUNDJune 2022September 2024Abandon2711NoNo
17836602IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOFJune 2022February 2024Allow2000YesNo
17834626PREVENTION OF ROSACEA INFLAMMATIONJune 2022December 2024Allow3011YesNo
17750698METHODS OF TREATING ELEVATED PLASMA CHOLESTEROLMay 2022December 2023Allow1901YesNo
17747084Chiral Indole Compounds and Their UseMay 2022July 2024Abandon2611YesNo
17739757METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLESMay 2022March 2025Allow3421YesNo
17735217Bromocriptine FormulationsMay 2022November 2023Allow1800YesNo
17735918CONTRACEPTIVE COMPOUNDS AND METHODSMay 2022May 2023Allow1200YesNo
17724537COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION-RELATED DISEASESApril 2022December 2023Allow2000YesNo
17720529EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETOApril 2022December 2024Abandon3211YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRAKUMAR, NIZAL S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
36.4%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
94
Allowed After Appeal Filing
37
(39.4%)
Not Allowed After Appeal Filing
57
(60.6%)
Filing Benefit Percentile
62.2%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHANDRAKUMAR, NIZAL S - Prosecution Strategy Guide

Executive Summary

Examiner CHANDRAKUMAR, NIZAL S works in Art Unit 1625 and has examined 2,471 patent applications in our dataset. With an allowance rate of 73.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.

Allowance Patterns

Examiner CHANDRAKUMAR, NIZAL S's allowance rate of 73.6% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by CHANDRAKUMAR, NIZAL S receive 1.23 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHANDRAKUMAR, NIZAL S is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +24.8% benefit to allowance rate for applications examined by CHANDRAKUMAR, NIZAL S. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 36.1% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 62.4% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 156.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 94.4% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 72.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.3% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.0% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.